Navigation Links
Experts predict Tamiflu could halve the pandemic influenza death toll versus no intervention

Treatment with the oral antiviral Tamiflu (oseltamivir) and prophylaxis for people exposed to infected patients could be one of the most cost-effective strategies for reducing illness and death during an influenza pandemic. According to modelling research presented by Beate Sander, University of Toronto, Canada, a stockpile of Tamiflu sufficient to cover 65% of a country’s population could cut deaths by approximately half. This study was announced at the leading influenza conference, Options for the Control of Influenza VI, in Toronto.1

The reality is that country stockpiles of Tamiflu are limited and are targeted at treatment only rather than treatment and prevention.2 However, some governments are now planning for sufficient antiviral stockpiles that will allow them to provide Tamiflu preventatively to close contacts of infected individuals.

The disease modelling research analysed for the first time the cost-effectiveness of strategies to reduce the spread of pandemic influenza using Tamiflu prophylactically. It was predicted that this preventative approach is likely to be more cost-effective than treating symptomatic patients alone and may be an effective and cost-saving measure for reducing the impact of pandemic influenza.1 This research is supported by an earlier analysis that indicates that a prevention strategy using Tamiflu may help contain a pandemic outbreak.3

The study also predicts that if the stockpile is increased so that there is an unlimited supply of Tamiflu for treating symptomatic patients and for preventing infection in people exposed to these patients (household contacts and school/work contacts), illness attack rates and deaths could potentially be reduced by more than half when compared to no intervention. This equates to a cost saving of $70,000 per 1,000 population which would save $21 billion in the US alone versus no intervention. Adding other strategies such as school closures further reduces the attack an d death rate and provides a health benefit at a reasonable cost. The research also showed that pre-pandemic vaccination programmes would play an important role but their effectiveness would be dependent upon how well the vaccine was matched to the virus.1

“The World Health Organisation provides a strong recommendation for the use of Tamiflu for the prevention of avian flu in people who have been in contact with someone who is known, or suspected of being infected with the virus,” commented Professor Ira Longini, Professor of Biostatistics and Mathematics at the University of Washington, Seattle, USA. “This research suggests that a similar approach may also be an effective strategy in the event of an actual pandemic outbreak, especially as it is unlikely that a vaccine fully matched to the strain will be available in the initial wave of a pandemic.”

Prophylaxis with antivirals or vaccines

Vaccination is the primary means of preventing influenza. However, at the beginning of a pandemic, supplies of vaccines which are fully matched to the pandemic strain will be limited or non-existent. This is because vaccine production can only start once the specific pandemic virus has been determined. The first doses of a matched vaccine are unlikely to become available within the early months of the pandemic, making prophylaxis and treatment with antivirals a crucial part in the efforts to reduce the burden of pandemic influenza.4

“In an environment full of uncertainties, it is best to have a comprehensive plan in place,” said Arnold Monto, professor of epidemiology and influenza expert at the University of Michigan. “Tamiflu is active against all types of influenza virus and will be immediately available during a pandemic if stockpiles are adequate. The big question is, should we be stockpiling for treatment only or for both treatment and prophylaxis"”
'"/>

Source:Ketchum


Related biology news :

1. Experts discuss use of human stem cells in ape and monkey brains
2. End of deforestation in view? Experts advance new way to size up global forest resources
3. Study identifies predictors of HIV drug resistance in patients beginning triple therapy
4. Biomarkers isolated from saliva successfully predict oral and breast cancer
5. Multiple-drug resistant gene expression pattern predicts treatment outcome for pediatric leukemia
6. Ocean climate predicts elk population in Canadian Rockies
7. Understanding biases in epidemic models important when making public health predictions
8. Identification of specific genes predicts which patients will respond to Hepatitis C treatment
9. UNC computer, marine scientists collaborate to predict flow of toxic waters from Katrina
10. Rensselaer researchers develop approach that predicts protein separation behavior
11. Researchers predict infinite genomes

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/11/2017)... 2017 NXT-ID, Inc. (NASDAQ:   NXTD ... the appointment of independent Directors Mr. Robin D. Richards ... of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief ... to their guidance and benefiting from their considerable expertise as ...
(Date:4/4/2017)... 2017   EyeLock LLC , a leader of ... States Patent and Trademark Office (USPTO) has issued U.S. ... of an iris image with a face image acquired ... company,s 45 th issued patent. ... given the multi-modal biometric capabilities that have recently come ...
(Date:3/29/2017)... -- higi, the health IT company that operates the largest ... , today announced a Series B investment from BlueCross ... new investment and acquisition accelerates higi,s strategy to create ... health activities through the collection and workflow integration of ... and secures data today on behalf of over 36 ...
Breaking Biology News(10 mins):
(Date:6/22/2017)... Ca (PRWEB) , ... June 22, 2017 , ... The ... It took 20 years until the first data on cross-contamination of human cell lines ... has been an increasing issue in cell culture labs and is associated with dramatic ...
(Date:6/20/2017)... ... June 20, 2017 , ... CTNext , Connecticut’s ... has formed a Higher Education Entrepreneurship Advisory Committee to implement the recommendations of ... other high-ranking representatives from 35 higher education institutions across the state over the ...
(Date:6/20/2017)... NEWTOWN SQUARE, Pa. , June 20, 2017 /PRNewswire/ ... technology, is pleased to announce the issuance of a ... treating gout or hyperuricemia by the U.S. Patent and ... Biotech Inc., a winner of the Buzz of Bio ... , is akin to developing non-drug approaches to ...
(Date:6/20/2017)... , ... June 20, 2017 , ... ... discovery of antibody therapeutics from millions-diverse immune repertoires, announces launch of its new ... Diego, California. Dave Johnson, PhD, CEO of GigaGen, will present on Surge at ...
Breaking Biology Technology: